Tag: Moffitt Cancer Center
-
Avelumab and Radiation Show Promise for Leptomeningeal Disease
Promising early results for avelumab plus radiation in leptomeningeal disease In a small but encouraging phase 1B study, researchers at Moffitt Cancer Center report that the immunotherapy drug avelumab, when given with whole-brain radiotherapy, may offer a new, potentially safer and more effective option for leptomeningeal disease (LMD). The findings, published in Neuro-Oncology, come from…
-
Avelumab with Radiation for Leptomeningeal Disease: Momentum
Introduction Leptomeningeal disease, in which cancer cells invade the membranes surrounding the brain and spinal cord, remains one of oncology’s most daunting challenges. Patients face rapid neurological decline, and survival is often measured in weeks to months. In a phase 1B study from Moffitt Cancer Center, researchers explored whether combining the immunotherapy drug avelumab with…
-
Avelumab with Radiation: Hope for Leptomeningeal Disease
Leptomeningeal disease: a high-stakes challenge in oncology Leptomeningeal disease, where cancer cells spread to the membranes surrounding the brain and spinal cord, remains one of oncology’s most formidable complications. Patients diagnosed with this condition often face survival measured in weeks to months, and treatment options are historically limited. In a hopeful development, researchers at Moffitt…